Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Meiji Seika Pharma Licenses Schizophrenia Treatment from MSD, to Market It Independently
April 18, 2013
- Novo Nordisk Ups Efforts in Basal Insulin Market, Pits Tresiba against Lantus
April 18, 2013
- Pfizer’s Palbociclib Receives Breakthrough Therapy Designation from US FDA
April 18, 2013
- Teijin, Kyorin Expected to Grow thru “Win-Win” Relationship: Teijin Pharma Pres.
April 17, 2013
- Teijin Pharma Hopes to Derive 50%-Plus of Sales from New Drugs by around 2016: Pres. Uno
April 17, 2013
- BMKK Sales Up 13% to 62 Billion Yen in 2012
April 17, 2013
- Nearly 43% of Pharmacies Now Receive Class 3 Fee for Generic Drug Dispensing Systems: Survey
April 17, 2013
- Astellas Appoints Dr Xue as Head of GPV
April 17, 2013
- FDA Accepts Otsuka Tolvaptan NDA for Priority Review
April 17, 2013
- Chugai Voluntarily Recalls Digosin Tablets
April 16, 2013
- Toho Holdings Establishes New Company for Distribution Management of Specialty Drugs
April 16, 2013
- MAA for Lurasidone Accepted in Australia: DSP
April 16, 2013
- Hisamitsu Sales Up 3.6% Helped by Mohrus Tape Sales Recovery
April 15, 2013
- Over Half of Domestic, Foreign-Affiliated Drug Makers Hired Fewer New Graduates This Year: Survey
April 15, 2013
- 11 Drug Makers to Increase, 11 to Decrease Hiring Next Year; Mid-Sized Companies Most Optimistic on Hiring
April 15, 2013
- Astellas to Conduct Interim Analysis for PIII Study of Enzalutamide in mCRPC within 2013
April 15, 2013
- Santen to Disclose Payments to Patient Groups in FY2014
April 15, 2013
- Pfizer Japan Launches Intestinal Amebiasis Treatment on April 12
April 12, 2013
- Daiichi Sankyo Sets Up Office of New Company Specialized in DMD Treatments
April 12, 2013
- Daiichi Sankyo Sets Up Office of New Company Specialized in DMD Treatments
April 12, 2013
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…